**Applications**
Adipotide was originally designed to treat obesity, specifically targeting the excessive accumulation of subcutaneous and visceral white adipose tissue. Preclinical research has focused on the following scenarios:
* **Improving obesity-related metabolic health:** In rhesus monkey models, Adipotide not only reduced body weight but also significantly improved insulin sensitivity; the amount of insulin required by the animals decreased by approximately 50% following treatment.
* **Neoadjuvant therapy prior to bariatric surgery:** Ablaris explored the use of Adipotide for preoperative weight loss in morbidly obese patients to reduce surgical complications and mortality rates.
* **Adjuvant intervention for obesity-related tumors:** A Phase 1 trial at MD Anderson enrolled patients with obesity and castration-resistant prostate cancer, as white adipose tissue produces factors that promote prostate cancer growth.
It must be emphasized that the scenarios mentioned above remain in the preclinical or incomplete clinical exploration stages; Adipotide has never been proven safe or effective in humans.
**Mechanism of Action**
Adipotide is a bifunctional chimeric peptide composed of two domains linked in tandem by a GG (Gly-Gly) linker:
* **Targeting domain (CKGGRAKDC):** This sequence recognizes and binds to prohibitin, a protein highly expressed on the surface of vascular endothelial cells within white adipose tissue.
* **Killing domain (D(KLAKLAK)₂):** A pro-apoptotic sequence composed entirely of D-amino acids. Upon entering the cell, this sequence targets the mitochondrial membrane, disrupting its integrity and triggering apoptosis.
**Mechanism logic:** Adipotide "anchors" itself to the vascular endothelium of adipose tissue via its targeting domain. After being internalized, the killing domain disrupts mitochondria, causing apoptosis in the microvascular endothelial cells of the adipose tissue. Once the blood supply is severed, the adipocytes undergo resorption and metabolism by the body due to hypoxia and nutrient deprivation.
This mechanism differs fundamentally from mainstream weight-loss drugs (such as GLP-1 receptor agonists): rather than suppressing appetite or blocking fat absorption, it physically disrupts the vascular bed of the adipose tissue.
"Benefits" in the Context of Bodybuilding
It must be stated at the outset: any use of Adipotide within the bodybuilding community constitutes self-experimentation and is unsupported by human data regarding safety or efficacy.
In the context of bodybuilding, the "theoretical appeal" of Adipotide stems primarily from preclinical data:
Targeting fat rather than muscle: In studies involving rhesus monkeys, lean monkeys did not experience weight loss after receiving Adipotide, suggesting that its action may be selective for white adipose tissue in obese individuals.
Potential irreversible reduction of adipocytes: Because the drug destroys the vascular bed of adipose tissue, theoretically, once fat is eliminated, the rate of "regrowth" may be slower than with conventional fat-loss methods.
Anecdotal exploration of spot reduction: Some bodybuilders have attempted to inject Adipotide into specific areas-such as "waist and abdominal fat"-claiming to observe localized fat loss; however, this method of use completely lacks scientific validation and carries a high risk of kidney injury.
Critical safety warning: In rhesus monkey studies, all animals receiving effective doses exhibited dose-dependent proximal renal tubule injury, manifested as elevated serum creatinine and abnormal urinalysis results. While these effects were reversible upon cessation of the drug, these observations were made under strictly monitored animal experimental conditions involving a short 28-day cycle. The scenarios of self-administered repeated use, high-dose use, or concurrent use with other nephrotoxic substances among bodybuilders are entirely incomparable.
Success Stories
Strictly speaking, there are no "success stories" for Adipotide, as no published human studies have demonstrated its safety or efficacy.
What can be objectively cited is data from animal experiments:
Obese rhesus monkeys (n=10 treatment, n=5 control): After 28 days of administration, body weight decreased by approximately 10.6%, BMI and abdominal circumference dropped significantly, abdominal fat decreased by 27%, and insulin resistance improved.
Obese mice: In earlier preclinical studies, Adipotide caused a weight loss of approximately 30% in mice.
However, these data cannot be equated to success in humans. Translating findings from rhesus macaques to humans involves significant uncertainty, particularly given species-specific differences in renal toxicity. The Phase 1 trial at MD Anderson, initiated around 2012, has yet to publish results-a fact that in itself serves as a significant negative signal.
Why Choose Us
(The following promotional text is based on the factory information you provided and is presented separately from the scientific facts above.)
As a primary manufacturer of Adipotide raw materials, our core strengths are built upon verifiable manufacturing capabilities:
Specialized Synthesis Equipment and Processes: We utilize Solid-Phase Peptide Synthesis (SPPS) technology combined with industrial-scale HPLC purification systems to ensure chemical structural consistency across every batch. As a bifunctional chimeric peptide, Adipotide is far more complex to synthesize than standard linear peptides, demanding exceptional equipment precision and process control.
Verifiable Purity: An HPLC purity report is provided for every batch, targeting a purity level of ≥98%. Substandard purity implies the presence of impurity peptides and by-products; for a compound with an inherently narrow safety margin, impurity control is a non-negotiable priority.
Supply Stability: As the primary manufacturer, we control the entire supply chain from raw materials to finished products. Our standard production cycles are stable, and bulk supply is not hindered by intermediaries.
Consistent Quality: We employ fixed synthesis routes, purification conditions, and quality control standards to ensure batch-to-batch consistency.
After-Sales Support: We provide a Certificate of Analysis (COA) for every batch, including HPLC chromatograms and mass spectrometry identification data, ensuring full traceability to the specific production batch.
We supply research-grade raw materials. Any purchase or use must comply with the laws of the relevant jurisdiction and be decided upon following a risk assessment by a qualified professional organization.
FAQ
Q: Where are you located?
A: Our products originate from Shenzhen, China.
Q: What is the minimum order quantity (MOQ)?
A: The minimum order quantity is 10 vials/sets.
Q: How soon do you ship?
A: Orders for in-stock items are shipped within 24 hours. Q: What purity levels do you offer?
A: The standard purity is 99%.
Q: Which shipping carriers do you use?
A: Options include FedEx, DHL, UPS, and postal services.
Q: How long does shipping take?
A: Approximately 10–15 days.
Q: Can you provide COA and HPLC test reports?
A: Yes, we can; all products undergo professional testing before shipment.
Q: Do you offer OEM services?
A: Yes, OEM services are available, subject to minimum order quantity (MOQ) requirements.
Q: How do you handle after-sales issues?
A: If a quality issue attributable to our production is confirmed after the customer receives the goods, we offer free replacement or a refund. We are committed to a pragmatic and responsible service approach, actively addressing and properly resolving any issues without evasion or excuses, while fully safeguarding our customers' interests.
Q: What payment methods do you accept?
A: We accept bank transfers, Bitcoin, TransferWise, and Xoom.
Hot Tags: chinese supplier of high-purity adipotide (2mg/vial) research-grade peptide, China chinese supplier of high-purity adipotide (2mg/vial) research-grade peptide manufacturers, suppliers, factory
